Navigation

PRESS RELEASES

Search all of our press releases here.

Search
Generic filters

Try these: Jeff GalvinC. David PauzaHIVFDAAmerican Gene Technologies

American Gene Technologies Appoints Dr. Robert R. Redfield as Special Advisor to the CEO

By AGT | Sep 15, 2021
Filed Under:

Dr. Redfield’s expertise in virology strengthens AGT’s capacity to develop innovative HIV treatments. American Gene Technologies (AGT) announces the appointment of Dr. Robert R. Redfield, former director of the Centers for Disease Control and Prevention (CDC) and co-founder of the Institute for Human Virology, as special advisor to AGT CEO Jeff Galvin. Dr. Redfield is well known for his decades… [Read More]

HIV Cure Program Releases Initial Clinical Trial Data

By AGT | Jul 16, 2021
Filed Under:

ROCKVILLE, MD, July 15, 2021 /Globe Newswire/ — American Gene Technologies (AGT) announced today that the Data and Safety Monitoring Board (DSMB) voted unanimously to continue AGT’s HIV cure program without modification, after safety analysis of the participant’s data revealed no adverse effects from the treatment. AGT’s Phase 1 trial of AGT103-T, a new cell and gene therapy for HIV… [Read More]

First Infusion Press Release

AGT Announces Progress with HIV Cure Program, Phase 1 Clinical Trial

By AGT | May 27, 2021
Filed Under:

ROCKVILLE, MD, May 27, 2021 /PR Newswire/ — American Gene Technologies (AGT), a clinical-stage biotechnology company, announced treatment of the first participant in its Phase I clinical trial to evaluate safety of the cell and gene therapy product AGT103-T. Designated as the RePAIR trial (Restore Potent Antiviral Immune Responses, NCT04561258), participants are infused once with their own CD4 T cells… [Read More]

LGBT+ investment firm Gaingels joins American Gene Technologies’ mission to cure HIV, and other serious human diseases

LGBT+ Investment Firm Gaingels Joins American Gene Technologies’ Mission to Cure HIV, and Other Serious Human Diseases

By AGT | Apr 14, 2021
Filed Under:

ROCKVILLE, Md., Apr. 15, 2021 /PRNewswire/ – American Gene Technologies (AGT), an emerging gene and cell therapy company, announced today that Gaingels, a leading venture investment syndicate in service of the LGBT+ community and its allies, made an investment in AGT to support the Phase 1 clinical trial of an HIV cure. The Phase 1 human trial is investigating the safety of… [Read More]

American Gene Technologies Announces First Trial Participant Enrolled in Phase 1 Study of AGT103-T Against HIV

By AGT | Nov 10, 2020
Filed Under:

ROCKVILLE, Md., Nov. 10, 2020 (GLOBE NEWSWIRE) — American Gene Technologies (AGT) announced today that the first trial participant was enrolled in the Phase 1 trial of AGT103-T, a new cell and gene therapy for HIV disease. The first trial participant underwent leukapheresis, a procedure for obtaining concentrated white blood cells, which will be used for manufacturing the AGT103-T cell product. After manufacturing… [Read More]

American Gene Technologies to Present at 2020 Virtual Cell & Gene Meeting on the Mesa

By AGT | Oct 8, 2020
Filed Under:

ROCKVILLE, Md., Oct. 08, 2020 (GLOBE NEWSWIRE) — American Gene Technologies (AGT) a cutting-edge cell and gene therapy company in Rockville, Maryland announced today that CEO Jeff Galvin will present at the annual Cell & Gene Meeting on the Mesa. The meeting will be held virtually October 12-16. Galvin’s presentation will highlight the company’s technology, including AGT103-T, a therapeutic intended to cure HIV, which… [Read More]

FDA Approves American Gene Technologies (AGT) To Move Forward With Phase 1 Clinical Trial Of HIV Cure Program

By AGT | Aug 11, 2020
Filed Under:

ROCKVILLE, Md., Aug. 11, 2020 /PRNewswire/ — American Gene Technologies (AGT) announced today approval by the FDA (Food and Drug Administration) to begin Phase 1, the first human clinical trial for AGT’s lead HIV program. AGT will conduct its Phase 1 study at clinical sites in the Baltimore/D.C. area, and has named Washington Health Institute, University of Maryland, Institute of Human Virology and Georgetown… [Read More]

Molecular Therapy Peer-Reviewed Article by AGT and NIAID Outlines Preclinical Data, Shows Potential for HIV Functional Cure

By AGT | Aug 3, 2020
Filed Under:

ROCKVILLE, Md., July 30, 2020 (GLOBE NEWSWIRE) — American Gene Technologies (AGT), an internationally recognized advanced gene and cell therapy company in Rockville, MD, today announced a coauthored article by scientists from AGT and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), regarding AGT’s promising cell and gene therapy for HIV. Through a collaboration… [Read More]

American Gene Technologies (AGT) Moves HQ to New Facility, Expands Lab Space for HIV and Cancer Cure Research – Across From National Cancer Institute Campus

By AGT | Jul 28, 2020
Filed Under:

Click on images to view larger ROCKVILLE, Md., July 28, 2020 — American Gene Technologies (AGT), an internationally recognized leading gene and cell therapy company in Rockville, Maryland, today announced it has leased a spacious, modern facility in the Maryland life sciences corridor, across from National Cancer Institute and Johns Hopkins Shady Grove Campus. The new facility will support AGT’s… [Read More]

American Gene Technologies to Present at 2020 Inborn Errors of Metabolism Drug Development Summit in Boston

By AGT | Mar 10, 2020
Filed Under:

ROCKVILLE, Md., March 10, 2020 (GLOBE NEWSWIRE) — American Gene Technologies (AGT), a leading gene and cell therapy company in Rockville, Maryland, is pleased to announce its Chief Science Officer C. David Pauza, Ph.D will present at the Inborn Errors of Metabolism Drug Development Summit in Boston, MA on March 11, 2020. Dr. Pauza will present how AGT used its proprietary, lentiviral… [Read More]

Subscribe to Press Release and News Updates

Subscribe to our press release and published article updates to be notified when we release new content!

Follow AGT on Social Media